GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncopeptides AB (OSTO:ONCO) » Definitions » E10

Oncopeptides AB (OSTO:ONCO) E10 : kr-7.52 (As of Sep. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Oncopeptides AB E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Oncopeptides AB's adjusted earnings per share data for the fiscal year that ended in Dec. 2023 was kr-1.967. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is kr-7.52 for the trailing ten years ended in Dec. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-12-12), Oncopeptides AB's current stock price is kr 1.54. Oncopeptides AB's E10 for the fiscal year that ended in Dec. 2023 was kr-7.52. Oncopeptides AB's Shiller PE Ratio of today is .


Oncopeptides AB E10 Historical Data

The historical data trend for Oncopeptides AB's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncopeptides AB E10 Chart

Oncopeptides AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -7.52

Oncopeptides AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -7.52 - - -

Competitive Comparison of Oncopeptides AB's E10

For the Biotechnology subindustry, Oncopeptides AB's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncopeptides AB's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncopeptides AB's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Oncopeptides AB's Shiller PE Ratio falls into.



Oncopeptides AB E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Oncopeptides AB's adjusted earnings per share data for the fiscal year that ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted) /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-1.967/131.9118*131.9118
=-1.967

Current CPI (Dec. 2023) = 131.9118.

Oncopeptides AB Annual Data

per_share_eps CPI Adj_EPS
201412 -0.607 100.225 -0.799
201512 -1.137 100.276 -1.496
201612 -2.302 102.022 -2.976
201712 -4.589 103.793 -5.832
201812 -6.827 105.912 -8.503
201912 -10.212 107.766 -12.500
202012 -18.222 108.296 -22.196
202112 -13.540 112.486 -15.878
202212 -2.929 126.365 -3.058
202312 -1.967 131.912 -1.967

Add all the adjusted EPS together and divide 10 will get our e10.


Oncopeptides AB  (OSTO:ONCO) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Oncopeptides AB E10 Related Terms

Thank you for viewing the detailed overview of Oncopeptides AB's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncopeptides AB Business Description

Traded in Other Exchanges
Address
Vastra Tradgardsgatan 15, Stockholm, SWE, SE-111 53
Oncopeptides AB is a biotech company focused on the research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Conjugate (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It has focused on the development of the product candidate Melflufen (Pepaxti), a peptide-conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Compounds. Melflufen is intended as an effective treatment for hematological cancers and in particular multiple myeloma.

Oncopeptides AB Headlines

From GuruFocus